DarioHealth, a digital chronic condition management platform, has expanded its GLP-1 offering with prescribing capabilities to capture a larger share of the weight-loss market. In collaboration with MediOrbis, Dario integrates prescribing into its GLP-1 behavior change solution for a comprehensive medical weight loss program.
The company noted that blockbuster drugs like Novo Nordisk's Ozempic and Wegovy have reshaped obesity and weight management. Dario’s end-to-end program combines behavior change with physician oversight to ensure GLP-1 medications are prescribed appropriately, preventing weight regain and supporting sustainable lifestyle changes. This approach aims to manage the entire weight-loss journey and maximize long-term results.
DarioHealth targets the direct-to-consumer market and positions itself as a key partner for employers, consumers, and pharma companies. In 2024, it partnered with a pharmaceutical firm to enhance engagement and gather insights on patient outcomes via DarioConnect. It also contracted with a Medicare Advantage plan to launch Twill by Dario, a behavioral health initiative, and acquired Twill for $22.4 million, adding peer-to-peer groups, expert consultations, and personalized education to its platform.
Further expansions include a Medicaid contract and the introduction of cardiometabolic solutions. Dario also launched an AARP benefit offering digital health and well-being solutions, set to debut this month.
Click here to read the original news story.